Literature DB >> 24029640

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Yoko Satoh1, Hiroshi Onishi, Atsushi Nambu, Tsutomu Araki.   

Abstract

PURPOSE: To evaluate the prognostic importance and predictive performance of volume-based parameters of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT).
MATERIALS AND METHODS: This study had institutional review board approval. All patients gave written informed consent for SBRT as well as for future anonymous use of clinical data. Data in 88 patients with stage I NSCLC (68 patients with T1N0M0 disease and 20 with T2aN0M0 disease) who had undergone FDG PET/CT and then SBRT were retrospectively evaluated. Seventy-seven tumors were histopathologically proved (48 adenocarcinomas, 24 squamous cell carcinomas, and five unspecified non-small cell carcinomas), and the remaining 11 tumors were diagnosed clinically without histopathologic diagnosis. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The MTV of the primary tumor was calculated as all voxels with an SUV of 2.5 or greater within the isocontour line, while TLG was calculated as MTV multiplied by the average SUV, by using fixed thresholds of either 50% (TLG50) or 60% (TLG60) of the maximum intratumoral FDG activity. The prognostic importance of PET parameters and other clinicopathologic variables (age, sex, tumor size, tumor location [peripheral or central], and biologically effective dose) was assessed by using Cox proportional hazards regression analysis of overall survival (OS) and disease-free survival (DFS) for both univariate and multiple-variable analyses.
RESULTS: The median follow-up period was 33 months. At 3 years, OS and DFS were 70.0% and 49.7%, respectively. In the univariate analyses, SUVmax (P = .001), MTV (P = .002), TLG50 (P = .001), and TLG60 (P < .001) were found to be significantly associated with DFS. In multiple variable analysis, these parameters were also significantly associated with DFS (P = .011 for SUVmax, P = .010 for MTV, P = .004 for TLG50, and P = .005 for TLG60). Only volumetric parameters (MTV, TLG50, and TLG60) were significant indicators of DFS in patients with tumors larger than 3 cm.
CONCLUSION: SUVmax, MTV, and TLG at FDG PET/CT have a prognostic role for patients with NSCLC treated with SBRT. When tumors are larger than 3 cm, only MTV and TLG are predictive of DFS. © RSNA, 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24029640     DOI: 10.1148/radiol.13130652

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  33 in total

1.  Getting published in Radiology: A Deputy Editor's perspective.

Authors:  Ali Guermazi; Herbert Y Kressel
Journal:  Jpn J Radiol       Date:  2015-08-05       Impact factor: 2.374

2.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

3.  Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.

Authors:  Yonglin Pu; James X Zhang; Haiyan Liu; Daniel Appelbaum; Jianfeng Meng; Bill C Penney
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-07       Impact factor: 9.236

4.  Prognostic value of radiomic analysis of iodine overlay maps from dual-energy computed tomography in patients with resectable lung cancer.

Authors:  Jooae Choe; Sang Min Lee; Kyung-Hyun Do; Jung Bok Lee; Sang Min Lee; June-Goo Lee; Joon Beom Seo
Journal:  Eur Radiol       Date:  2018-07-27       Impact factor: 5.315

5.  In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.

Authors:  Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

6.  Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung.

Authors:  Xiang-Rong Zhao; Yong Zhang; Yong-Hua Yu
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

7.  Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.

Authors:  Yifei Ma; Wei Xu; Ruojing Bai; Yiming Li; Hongyu Yu; Chunshan Yang; Huazheng Shi; Jian Zhang; Jidong Li; Chenguang Wang; Jianru Xiao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-07       Impact factor: 9.236

8.  Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas.

Authors:  Dhaval Patel; Amit Mehta; Naris Nilubol; William Dieckmann; Karel Pacak; Electron Kebebew
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

9.  Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

Authors:  M Dosani; R Yang; M McLay; D Wilson; M Liu; C J Yong-Hing; J Hamm; C R Lund; R Olson; D Schellenberg
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 10.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.